Cannabis Schedule III Rescheduling Impact on Medical Research and Patients
The potential rescheduling of cannabis from Schedule I to Schedule III represents a significant regulatory shift that could reduce research barriers and accelerate clinical investigation. Cannabis schedule III rescheduling would lower DEA registration…
Patient First Coalition Supports DEA’s Medical Cannabis Review Process
The DEA medical cannabis review process is a pivotal step toward rescheduling cannabis to Schedule III. This change could expand clinical research opportunities and improve patient access to standardized cannabis therapies. The Patient First Coalition…
Federal Schedule III shift triggers D.C., Maryland cannabis uncertainty – Outlaw Report
Federal rescheduling of cannabis to Schedule III would fundamentally change how physicians approach cannabis medicine, moving from state recommendations to federal prescriptions. This regulatory shift creates both opportunities for standardized cannabis…
What the 2026 DOJ Rescheduling Order Means in Practice
On April 23, 2026, the U.S. DOJ moved state-licensed medical cannabis to Schedule III, the first federal acknowledgment of accepted medical value in 55 years. Dr. Caplan breaks down what actually changed for patients, physicians, and the research…
Terrapin Urges State Action After DOJ Medical Marijuana Rescheduling
The DOJ medical marijuana rescheduling impact signals a major federal policy shift from Schedule I to Schedule III. This change could improve research access and reduce barriers for patients. States are now urged to adapt their medical cannabis programs…
New Mexico Cannabis Businesses Eye Tax Breaks After Federal Rescheduling
The 2026 cannabis tax break potential could significantly reduce operational costs for New Mexico cannabis businesses. Federal rescheduling from Schedule I to Schedule III would eliminate IRS Section 280E restrictions. This change may improve product…
Medical Marijuana Moves to Schedule III, Boosting Research and Tax Relief
Schedule III cannabis research is opening new doors for medical marijuana by reducing regulatory hurdles. This reclassification allows more rigorous clinical trials and tax relief for cannabis businesses. Patients may benefit from improved access and…
UNLV Scientists on Federal Cannabis Schedule III Reclassification Impact
The federal Schedule III reclassification of cannabis creates significant cannabis legality confusion that affects clinical practice. Clinicians need clarity on what this regulatory change means for patient care. This article explains the implications of…
What the DOJ Cannabis Order Means for Patients and Clinicians
The medical cannabis Schedule III order is a major federal policy change, but it is not the same as new clinical proof. This Evidence Watch explains what the DOJ action may mean for research access, patient care, and regulated medical cannabis programs.…
Changes Could Be Coming to Oklahoma After Medical Marijuana Reclassified – KOCO
The medical marijuana reclassification impacts Oklahoma's regulatory landscape significantly. Federal cannabis rescheduling to Schedule III may improve research and insurance coverage. Patients and clinicians should monitor evolving state and federal…